查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1629276

肺动脉高压 (PAH) 治疗市场，按药物类别、给药途径、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Pulmonary Arterial Hypertension (PAH) Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年肺动脉高压（PAH）治疗市值为79.8043亿美元，2024年至2032年复合年增长率为5.90%。

肺动脉高压（PAH）治疗市场-市场动态

肺动脉高压（PAH）盛行率的增加预计将推动市场的成长

随着全球人口老化，肺动脉高压（PAH）的盛行率预计将会增加，特别是在更容易出现慢性健康问题的老年人中。随后患有 PAH 的慢性病患者数量不断增加，可能需要采取综合管理方法，从而增加对各种治疗替代方案的需求。 PAH 被归类为一种罕见疾病，盛行率估计为每百万人 10 至 52 例。根据欧洲呼吸学会的说法，PAH（1型肺动脉高压）根据潜在的疾病机制进一步划分。儘管如此，增加对临床研究的投资可能会促进新疗法的出现，从而拓宽市场。相反，医疗保健专业人员的意识有限可能会阻碍市场扩张。

肺动脉高压 (PAH) 治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 5.90% 左右的复合年增长率成长

根据药物类别细分，预计内皮素受体拮抗剂 (ERA) 将在 2023 年显示最大的市场份额

根据给药途径细分，口服药物是 2023 年领先的药物类别

根据配销通路细分，医院药房是 2023 年领先的药品类别

按地区划分，北美是 2023 年的主要收入来源

肺动脉高压（PAH）治疗市场-細項分析：

全球肺动脉高压（PAH）治疗市场根据药物类别、给药途径、配销通路和地区进行细分。

根据药物类别，市场分为四个部分：前列环素和前列环素类似物、磷酸二酯酶5 (PDE 5) 抑制剂、内皮素受体拮抗剂(ERA) 和可溶性鸟苷酸环化酶(SGC) 刺激剂。其中，内皮素受体拮抗剂（ERA）在市场上占据主导地位。 ERA 在肺动脉高压 (PAH) 的治疗中至关重要，因为它们抑制内皮素的作用，内皮素是一种血管收缩剂，可导致与 PAH 相关的肺动脉血压升高。

根据给药途径，市场分为三类：口服、静脉/皮下和吸入。口服品类是市场成长的主要驱动力。口服疗法对于肺动脉高压（PAH）尤其重要，因为它们给药方便，通常适合长期使用，并增强患者的依从性，特别是对于需要持续治疗这种慢性疾病的个体。

根据配销通路，市场分为三类：医院药房、零售药房和线上药房。医院药房在市场上占据主导地位。它们是 PAH 药物的主要配销通路，特别是需要密切医疗监督的治疗，包括静脉注射和注射治疗。

肺动脉高压 (PAH) 治疗市场 - 地理洞察

北美地区凭藉其先进的医疗基础设施和专业医疗设施引领市场。北美的医疗保健提供者受益于最先进的诊断和治疗技术，这些技术增强了疾病管理并带来更好的患者治疗结果。根据美国医学会统计，2022年美国医疗支出成长4.1%，达到4.5兆美元，即人均13,493美元。这一成长率与疫情前的数据一致，2019 年也为 4.1%。随着意识和诊断能力的不断提高，多环芳烃治疗市场预计将在多个地区持续成长。

肺动脉高压（PAH）治疗市场-竞争格局：

肺动脉高压（PAH）治疗市场的特点是竞争激烈，许多製药公司致力于为这种慢性且可能致命的疾病创造突破性的疗法。这些公司的普遍策略是持续投资临床试验，旨在评估新疗法、组合和剂型，因为这些进步可能会重新定义 PAH 的护理标准。此外，许多组织正在扩大其在新兴市场的业务，这些市场对 PAH 的认识和诊断不断增强，以获得竞争优势。

最新进展：

在获得美国食品药物管理局的初步批准后，一种名为Yutrepia 的新型曲前列环素製剂可能很快可供患有肺动脉高压(PAH) 和与间质性肺部疾病(PH-ILD) 相关的肺动脉高压的患者使用。

辉瑞宣布，一项旨在评估静脉注射(IV) 西地那非联合吸入一氧化氮(iNO) 治疗新生儿持续性肺动脉高压(PPHN) 的有效性和安全性的3 期临床试验并未实现其主要疗效目标。

目录

第 1 章：肺动脉高压 (PAH) 治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的肺动脉高压 (PAH) 治疗市场片段
    • 按给药途径分類的肺动脉高压 (PAH) 治疗市场摘要
    • 按配销通路分類的肺动脉高压 (PAH) 治疗市场片段
    • 肺动脉高压 (PAH) 治疗市场片段（按国家/地区）
    • 按地区分類的肺动脉高压 (PAH) 治疗市场片段
  • 竞争洞察

第 3 章：肺动脉高压 (PAH) 治疗主要市场趋势

  • 肺动脉高压（PAH）治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 肺动脉高压（PAH）治疗市场限制
    • 市场限制影响分析
  • 肺动脉高压（PAH）治疗市场机会
  • 肺动脉高压（PAH）治疗市场未来趋势

第 4 章：肺动脉高压 (PAH) 治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：肺动脉高压 (PAH) 治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：肺动脉高压 (PAH) 治疗市场格局

  • 2023 年肺动脉高压 (PAH) 治疗市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：肺动脉高压 (PAH) 治疗市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 前列环素和前列环素类似物
    • 磷酸二酯酶 5 (PDE 5) 抑制剂
    • 内皮素受体拮抗剂 (ERA)
    • 可溶性鸟苷酸环化酶 (SGC) 刺激剂

第 8 章：肺动脉高压 (PAH) 治疗市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 口服
    • 静脉注射/皮下注射
    • 吸入式

第 9 章：肺动脉高压 (PAH) 治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 10 章：肺动脉高压 (PAH) 治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美肺动脉高压 (PAH) 治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲肺动脉高压 (PAH) 治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区肺动脉高压 (PAH) 治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲肺动脉高压 (PAH) 治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲肺动脉高压 (PAH) 治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 肺动脉高压 (PAH) 治疗产业

  • 竞争仪表板
  • 公司简介
    • United Therapeutics Ltd.
    • Bayer AG
    • Actelion Ltd.
    • Pfizer, Inc.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceuticals Inc.
    • Eli Lilly and Company
    • Steady Med Ltd.
    • Johnson & Johnson Services, Inc.
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4444

REPORT HIGHLIGHT

The Pulmonary Arterial Hypertension (PAH) Treatment Market was valued at USD 7,980.43 million in 2023 and expanded at a CAGR of 5.90% from 2024 to 2032.

Pulmonary Arterial Hypertension (PAH) is an uncommon yet significant medical condition marked by increased blood pressure within the pulmonary arteries, potentially resulting in heart failure and various other complications. The primary objective of PAH treatment is to alleviate symptoms, enhance the quality of life, and decelerate the progression of the disease. Consistent monitoring of symptoms, functional capacity, and the effectiveness of treatment are essential for the successful management of PAH. Typically, a multidisciplinary team of healthcare professionals, including cardiologists, pulmonologists, and pulmonary medicine specialists, collaborates to provide thorough management of the condition.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Market Dynamics

Increasing Prevalence of Pulmonary Arterial Hypertension (PAH) is anticipated to drive the growth of the market

As the global demographic shifts towards an older population, the prevalence of pulmonary arterial hypertension (PAH) is anticipated to increase, especially among elderly individuals who are more vulnerable to chronic health issues. The rising number of patients with chronic diseases who subsequently develop PAH will likely necessitate comprehensive management approaches, thereby heightening the demand for various treatment alternatives. PAH is classified as a rare condition, with prevalence estimates ranging from 10 to 52 cases per million individuals. According to the European Respiratory Society, PAH (Group 1 pulmonary hypertension) is further divided based on the underlying disease mechanisms. Nevertheless, enhanced investment in clinical research may facilitate the emergence of novel therapies, thereby broadening the market. Conversely, limited awareness among healthcare professionals could hinder market expansion.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2024-2032)

Based on Drug Class segmentation, Endothelin Receptor Antagonists (ERA) was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading Drug Class in 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Pulmonary Arterial Hypertension (PAH) Treatment Market- Segmentation Analysis:

The Global Pulmonary Arterial Hypertension (PAH) Treatment Market is segmented based on Drug Class, Route of Administration, Distribution Channel, and Region.

The market is categorized into four segments according to Drug Class: Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA), and Soluble Guanylate Cyclase (SGC) Stimulators. Among these, Endothelin Receptor Antagonists (ERAs) holds a dominant position in the market. ERAs are essential in the treatment of pulmonary arterial hypertension (PAH) as they inhibit the effects of endothelin, a vasoconstrictor that contributes to elevated blood pressure in the pulmonary arteries associated with PAH.

The market is segmented into three categories according to the Route of Administration: Oral, Intravenous/Subcutaneous, and Inhalational. The Oral category is the primary driver of market growth. Oral therapies are especially significant for pulmonary arterial hypertension (PAH) as they provide convenience in administration, are generally appropriate for long-term use, and enhance patient adherence, particularly for individuals needing continuous management of this chronic illness.

The market is segmented into three categories according to the Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies hold a dominant position in the market. They function as the principal distribution channel for PAH medications, particularly for therapies that necessitate close medical oversight, including intravenous and injectable treatments.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Geographical Insights

The North American region leads the market, attributed to its advanced healthcare infrastructure and specialized medical facilities. Healthcare providers in North America benefit from access to state-of-the-art diagnostic and therapeutic technologies, which enhance disease management and lead to better patient outcomes. According to the American Medical Association, health expenditures in the United States rose by 4.1% in 2022, reaching USD 4.5 trillion, or USD 13,493 per capita. This growth rate aligns with pre-pandemic figures, which also stood at 4.1% in 2019. Meanwhile, the Asia-Pacific region offers significant growth potential, driven by a strong focus on research and development. As awareness and diagnostic capabilities continue to advance, the PAH treatment market is expected to experience sustained growth across multiple regions.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Competitive Landscape:

The market for Pulmonary Arterial Hypertension (PAH) treatment is characterized by intense competition, with a multitude of pharmaceutical firms dedicated to creating groundbreaking therapies for this chronic and potentially fatal condition. A prevalent strategy among these companies is the ongoing investment in clinical trials aimed at evaluating new therapies, combinations, and dosage forms, as such advancements may redefine the standards of care for PAH. Additionally, many organizations are broadening their operations in emerging markets, where there is an increasing awareness and diagnosis of PAH, to gain a competitive advantage.

Recent Developments:

A novel formulation of treprostinil, known as Yutrepia, may soon be accessible to individuals suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), following the tentative approval granted by the Food and Drug Administration (FDA) earlier this month.

Pfizer Inc. has announced that a Phase 3 clinical trial aimed at evaluating the efficacy and safety of intravenous (IV) sildenafil in conjunction with inhaled nitric oxide (iNO) for treating newborns with Persistent Pulmonary Hypertension (PPHN) did not achieve its primary efficacy objective.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • United Therapeutics Ltd.
  • Bayer AG
  • Actelion Ltd.
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Steady Med Ltd.
  • Johnson & Johnson Services, Inc.
  • Others

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Prostacyclin and Prostacyclin Analogs
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Endothelin Receptor Antagonists (ERA)
  • Soluble Guanylate Cyclase (SGC) Stimulator

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous/ subcutaneous
  • Inhalational

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pulmonary Arterial Hypertension (PAH) Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Drug Class
    • 2.1.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Route of Administration
    • 2.1.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Distribution Channel
    • 2.1.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Country
    • 2.1.5. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Pulmonary Arterial Hypertension (PAH) Treatment Key Market Trends

  • 3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Opportunities
  • 3.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Future Trends

4. Pulmonary Arterial Hypertension (PAH) Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pulmonary Arterial Hypertension (PAH) Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Pulmonary Arterial Hypertension (PAH) Treatment Market Landscape

  • 6.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Prostacyclin and Prostacyclin Analogs
    • 7.1.3. Phosphodiesterase 5 (PDE 5) Inhibitors
    • 7.1.4. Endothelin Receptor Antagonists (ERA)
    • 7.1.5. Soluble Guanylate Cyclase (SGC) Stimulator

8. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Intravenous/ subcutaneous
    • 8.1.4. Inhalational

9. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Pulmonary Arterial Hypertension (PAH) Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Pulmonary Arterial Hypertension (PAH) Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. United Therapeutics Ltd.
    • 11.2.2. Bayer AG
    • 11.2.3. Actelion Ltd.
    • 11.2.4. Pfizer, Inc.
    • 11.2.5. Gilead Sciences, Inc.
    • 11.2.6. GlaxoSmithKline plc
    • 11.2.7. Teva Pharmaceuticals Inc.
    • 11.2.8. Eli Lilly and Company
    • 11.2.9. Steady Med Ltd.
    • 11.2.10. Johnson & Johnson Services, Inc.
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us